12 completed, 4 terminated. 12 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 9, Terminated 3 |
| Phase 2 | 10 | Completed 7, Terminated 3 |
Follow CB-839: new trials by email Literature Review of CB-839 trials Research Report on CB-839
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients Cohort 1: Dose Escalation, Cohort 2: Dose Escalation - Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer | Phase 1 | Terminated | University of Alabama at Birmingham | 1 | 2021-09-01 | 2023-11-21 |
| Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects Telaglenastat, Famotidine, Placebo for famotidine - Drug Interaction | Phase 1 | Completed | Calithera Biosciences, Inc | 22 | 2020-09-22 | 2021-03-09 |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy - Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer | Phase 2 | Terminated | Calithera Biosciences, Inc | 40 | 2020-07-24 | 2022-09-21 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance] - Solid Tumors, NSCLC | Phase 1 / Phase 2 | Completed | Calithera Biosciences, Inc | 53 | 2019-06-25 | 2022-09-19 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors CB-839, Talazoparib - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 33 | 2019-05-20 | 2022-02-17 |
| CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma CB-839, Cabozantinib, Placebo - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Calithera Biosciences, Inc | 444 | 2018-04-24 | 2023-03-20 |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Azacitidine, Glutaminase Inhibitor CB-839 - Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 28 | 2017-11-15 | 2024-05-14 |
| CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) Placebo, CB-839, everolimus - Clear Cell Renal Cell Carcinoma | Phase 2 | Completed | Calithera Biosciences, Inc | 69 | 2017-09-06 | 2022-09-15 |
| Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer Glutaminase Inhibitor CB-839, Panitumumab, Irinotecan Hydrochloride (phase I only) - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 29 | 2017-08-23 | 2024-08-30 |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Paclitaxel, CB-839 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Completed | Calithera Biosciences, Inc | 52 | 2017-05-01 | 2022-09-28 |
| A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults CB-839 Capsules, CB-839 Tablets - Healthy Volunteers | Phase 1 | Completed | Calithera Biosciences, Inc | 14 | 2016-10-01 | 2017-01-04 |
| CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer CB-839, Capecitabine - Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | David Bajor, MD | 50 | 2016-09-12 | 2024-12-19 |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) CB-839, Nivolumab - Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 118 | 2016-08-01 | 2023-03-17 |
| Study of the Glutaminase Inhibitor CB-839 in Leukemia CB-839, CB-Aza - Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Phase 1 | Completed | Calithera Biosciences, Inc | 43 | 2014-03-01 | 2017-02-09 |
| Study of the Glutaminase Inhibitor CB-839 in Solid Tumors CB-839, Pac-CB, CBE - Solid Tumors, Triple-Negative Breast Cancer | Phase 1 | Completed | Calithera Biosciences, Inc | 210 | 2014-02-01 | 2022-07-20 |
| Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone - Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma | Phase 1 | Completed | Calithera Biosciences, Inc | 25 | 2014-02-01 | 2018-07-18 |
Carcinoma, Renal Cell (5) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Colonic Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Kidney Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Mesothelioma (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Calithera Biosciences, Inc (12) · David Bajor, MD (1) · M.D. Anderson Cancer Center (1) · University of Alabama at Birmingham (1) · Vanderbilt-Ingram Cancer Center (1)
United States (15) · Australia (2) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · Spain (1) · United Kingdom (1)
Sam Whiting, MD, PhD (3) · Emil Kuriakose, MD (2) · Keith W Orford, MD, PhD (2) · Courtney DiNardo (1) · David Bajor, MD (1) · Jeffery Peterson, MD (1) · Jordan Berlin, MD (1) · Paul Griffin, Dr. (1) · Rebecca Arend, MD (1) · Sam Whiting (1) · Sam Whiting, M.D., Ph.D. (1) · Samuel Whiting, MD, PhD (1)
PMID 39462179, PMID 35576438, PMID 36048457, PMID 39300320, PMID 40847194
R01CA206210 (1)